Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital

Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA

USFDA completes GMP inspection at Dr. Reddy's Laboratories’ API Middleburgh facility

The United States Food & Drug Administration (USFDA) completed a GMP inspection at our API Middleburgh facility in New York. The inspection was conducted from 12 May, 2025 to 16 May, 2025 (US EST time). The company has been issued a Form 483 with 2 observations, which we will address within the stipulated timeline.

Relonchem receives marketing uthorization for the product Gabapentin 50 mg/ml oral solution

Marksans Pharma Limited announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency. 

Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA

Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited, Unit-1 received EIR from USFDA and the site is classified as VAI. The inspection was carried out at unit-1 by USFDA between March 3-7, 2025.

Shanmuga Hospital installs Robotic Surgical equipment

Shanmuga Hospital Ltd has announced that the purchase of Robotic Surgical Equipment has been completed successfully and installed. The new equitpment has become operational with effect from 10th May 2025. The first surgical procedure using the Robotic Surgical Equipment was successfully conducted on the same day. At the time of the Initial Public Offering (IPO), the company had proposed to utilize a portion of the IPO proceeds for the purchase of Robotic Surgical Equipment.